Contrast-enhanced ultrasonography–CT/MRI fusion guidance for percutaneous ablation of inconspicuous, small liver tumors: improving feasibility and therapeutic outcome

医学 射频消融术 放射科 经皮 烧蚀 超声造影 肝肿瘤 肝细胞癌 超声波 超声科 内科学
作者
Yuna Lee,Jeong Hee Yoon,Seung-Wan Han,Ijin Joo,Jeong Min Lee
出处
期刊:Cancer Imaging [Springer Nature]
卷期号:24 (1)
标识
DOI:10.1186/s40644-023-00650-y
摘要

Percutaneous radiofrequency ablation (RFA) is pivotal for treating small malignant liver tumors, but tumors often remain inconspicuous on B-mode ultrasound (US). This study evaluates the potential of CEUS-CT/MRI fusion imaging (FI) to improve tumor visibility and the associated RFA outcomes for small (≤ 3 cm) malignant liver tumors that were inconspicuous on US.Between January 2019 and April 2021, a prospective study enrolled 248 patients with liver malignancies (≤ 3 cm) that were poorly visible on B-mode US. Tumor visibility and ablation feasibility were assessed using B-mode US, US-CT/MRI FI, and CEUS-CT/MRI FI, and graded on a 4-point scale. CEUS was employed post-registration of US and CT/MRI images, utilizing either SonoVue or Sonazoid. Comparisons between US-based and CEUS-based fusion visibility and feasibility scores were undertaken using the Friedman test. Moreover, rates of technical success, technique efficacy, local tumor progression (LTP), and major complications were assessed.The cohort included 223 hepatocellular carcinomas (HCCs) (89.9%) and 23 metastases (9.3%), with an average tumor size of 1.6 cm. CEUS-CT/MRI FI demonstrated a significant advantage in tumor visibility (3.4 ± 0.7 vs. 1.9 ± 0.6, P < 0.001) and technical feasibility (3.6 ± 0.6 vs. 2.9 ± 0.8, P < 0.001) compared to US-FI. In 85.5% of patients, CEUS addition to US-FI ameliorated tumor visibility. Technical success was achieved in 99.6% of cases. No severe complications were reported. One and two-year post CEUS-CT/MRI FI-guided RFA estimates for LTP were 9.3% and 10.9%, respectively.CEUS-CT/MRI FI significantly improves the visualization of tumors not discernible on B-mode US, thus augmenting percutaneous RFA success and delivering improved therapeutic outcomes.ClinicalTrials.gov, NCT05445973. Registered 17 June 2022 - Retrospectively registered, http://clinicaltrials.gov/study/NCT05445973?id=NCT05445973&rank=1 .

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
yeah完成签到,获得积分10
1秒前
英勇的幻露完成签到,获得积分10
1秒前
快乐小白菜完成签到,获得积分10
1秒前
1秒前
种子完成签到,获得积分10
2秒前
点金石完成签到,获得积分10
3秒前
隐形曼青应助fwz采纳,获得10
4秒前
5秒前
5秒前
憨憨的小于完成签到,获得积分10
5秒前
Luyt完成签到 ,获得积分10
6秒前
PsyQin完成签到,获得积分10
6秒前
6秒前
量子星尘发布了新的文献求助10
7秒前
Aurora的努力日记完成签到,获得积分10
7秒前
8秒前
华仔应助dyfsj采纳,获得10
8秒前
领导范儿应助Dun采纳,获得10
8秒前
8秒前
朴素访云完成签到,获得积分10
9秒前
9秒前
青衣发布了新的文献求助10
9秒前
飘来一朵云完成签到,获得积分10
9秒前
时尚的菠萝完成签到,获得积分10
9秒前
NOV完成签到,获得积分10
10秒前
红豆大王完成签到,获得积分10
10秒前
田様应助可靠豌豆采纳,获得10
10秒前
奋斗人雄完成签到,获得积分0
10秒前
11秒前
苏东方完成签到,获得积分10
11秒前
Lisiqi完成签到,获得积分10
11秒前
11秒前
哈哈哈发布了新的文献求助10
11秒前
落后的小伙完成签到,获得积分20
12秒前
ikun完成签到,获得积分10
14秒前
搞怪的访琴完成签到,获得积分10
14秒前
kiki完成签到,获得积分10
15秒前
整整完成签到,获得积分10
16秒前
李卓发布了新的文献求助10
16秒前
wshh完成签到,获得积分10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Handbook of pharmaceutical excipients, Ninth edition 5000
Aerospace Standards Index - 2026 ASIN2026 3000
Signals, Systems, and Signal Processing 610
Discrete-Time Signals and Systems 610
Principles of town planning : translating concepts to applications 500
Social Work and Social Welfare: An Invitation(7th Edition) 410
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 纳米技术 有机化学 物理 生物化学 化学工程 计算机科学 复合材料 内科学 催化作用 光电子学 物理化学 电极 冶金 遗传学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 6059338
求助须知:如何正确求助?哪些是违规求助? 7891939
关于积分的说明 16298463
捐赠科研通 5203536
什么是DOI,文献DOI怎么找? 2783979
邀请新用户注册赠送积分活动 1766672
关于科研通互助平台的介绍 1647175